Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Cyclocreatine treatment improves cognition in mice with creatine transporter deficiency
Yuko Kurosawa, … , Stephen C. Benoit, Joseph F. Clark
Yuko Kurosawa, … , Stephen C. Benoit, Joseph F. Clark
Published July 2, 2012
Citation Information: J Clin Invest. 2012;122(8):2837-2846. https://doi.org/10.1172/JCI59373.
View: Text | PDF
Research Article Neuroscience Article has an altmetric score of 30

Cyclocreatine treatment improves cognition in mice with creatine transporter deficiency

  • Text
  • PDF
Abstract

The second-largest cause of X-linked mental retardation is a deficiency in creatine transporter (CRT; encoded by SLC6A8), which leads to speech and language disorders with severe cognitive impairment. This syndrome, caused by the absence of creatine in the brain, is currently untreatable because CRT is required for creatine entry into brain cells. Here, we developed a brain-specific Slc6a8 knockout mouse (Slc6a8–/y) as an animal model of human CRT deficiency in order to explore potential therapies for this syndrome. The phenotype of the Slc6a8–/y mouse was comparable to that of human patients. We successfully treated the Slc6a8–/y mice with the creatine analog cyclocreatine. Brain cyclocreatine and cyclocreatine phosphate were detected after 9 weeks of cyclocreatine treatment in Slc6a8–/y mice, in contrast to the same mice treated with creatine or placebo. Cyclocreatine-treated Slc6a8–/y mice also exhibited a profound improvement in cognitive abilities, as seen with novel object recognition as well as spatial learning and memory tests. Thus, cyclocreatine appears promising as a potential therapy for CRT deficiency.

Authors

Yuko Kurosawa, Ton J. DeGrauw, Diana M. Lindquist, Victor M. Blanco, Gail J. Pyne-Geithman, Takiko Daikoku, James B. Chambers, Stephen C. Benoit, Joseph F. Clark

×

Figure 4

Phosphorylated metabolites in the brain, measured by 31P-MRS.

Options: View larger image (or click on image) Download as PowerPoint
Phosphorylated metabolites in the brain, measured by 31P-MRS.
 
An indir...
An indirect measure of the phosphate metabolites was determined by taking the peak height of the metabolite of interest and dividing by the sum of all the other phosphate metabolites. (A) Baseline measurements (n = 3 per group) of inorganic phosphate (Pi), phosphocreatine (PCr), and β-adenosine triphosphate (β-ATP). (B) Ratio of phosphocreatine plus phosphorylated cyclocreatine (PcCr) to total phosphorylated metabolites after 9 weeks of treatment (n = 3 per group). Data are mean ± SEM. *P ≤ 0.05, **P ≤ 0.01 vs. Slc6a8fl/y.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Blogged by 2
Posted by 8 X users
Referenced in 7 patents
Referenced in 1 Wikipedia pages
Reddited by 1
119 readers on Mendeley
See more details